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bjectives We sought to analyze the outcomes of transcatheter patent ductus arteriosus (PDA) oc-
lusion using a variety of devices in infants weighing 6 kg.
ackground Indications for transcatheter closure of a PDA in infancy include congestive heart fail-
re and/or failure to thrive. Devices available for small infants may be problematic for various rea-
ons, including sheath size, stiffness of delivery system, and anchoring and retrievability characteris-
ics of the device. The Amplatzer Ductal Occluder is approved by U.S. Food and Drug Administration
or children weighing 6 kg and older than 6 months of age.
ethods We performed a multicenter, retrospective analysis of children weighing 6 kg in whom
ranscatheter PDA occlusion was attempted between January 1995 and November 2005 at Texas
hildren’s Hospital and January 2001 to November 2005 at Children’s Hospital of San Diego.
esults A total of 62 patients underwent attempted closure. The mean age at catheterization was
.7  2.8 months with a mean weight at catheterization of 4.6  0.9 kg. Successful device place-
ent was achieved in 58 of 62 patients (94%). Among those receiving a device, complete occlusion
as noted in all 58 patients at either catheterization or last available follow-up.
onclusions Percutaneous closure of PDA should be considered even in infants 6 kg. (J Am Coll
ardiol Intv 2010;3:1295–9) © 2010 by the American College of Cardiology Foundation
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1296ndications for transcatheter closure of a patent ductus
rteriosus (PDA) in infancy include symptoms of congestive
eart failure, failure to thrive, and evidence of left ventric-
lar volume overload (1). Devices currently available for
ranscatheter closure of PDA in the U.S. include coils, the
mplatzer Duct Occluder (ADO), and the Gianturco-
rifka Vascular Occluder Device. When applied in small
nfants, each of these may be problematic for one or more of
he following reasons: relatively large sheath size for small
essels, stiffness of the delivery system with resultant hemo-
ynamic instability during device deployment, risk of pro-
rusion of the device into the aorta or pulmonary artery,
oor anchoring or stability within the PDA, and difficult
etrievability (2). These devices (e.g., coils), which are used
off label,” do not have specific weight or age recommen-
ations, but the current manufacturer recommendations for
he ADO are a weight 6 kg and age 6 months.
Numerous studies have documented the feasibility of
atheter-based closure of PDA in older children and adults,
owever, there is a paucity of data regarding the outcomes
f percutaneous closure of PDA in small infants, and in
articular, there are no published criteria establishing a
minimal weight of 6 kg as a
suitable cutoff. We therefore
performed a multicenter, retro-
spective analysis of children
weighing 6 kg in whom trans-
catheter PDA occlusion was at-
tempted between January 1995
and November 2005 at Texas
Children’s Hospital and January
2001 to November 2005 at
hildren’s Hospital of San Diego.
ethods
nstitutional Review Board approval was obtained at both
nstitutions. A retrospective analysis of children 6 kg in
hom transcatheter PDA occlusion was attempted between
anuary 1, 1995 and November 1, 2005, at Texas Children’s
ospital and between January 1, 2001 and November 1,
005, at Children’s Hospital San Diego was conducted. The
ardiology databases at both institutions were searched for
ligible patients. The indications for the procedure and any
ssociated congenital heart defects were recorded, as were
atient weight, angiographic PDA minimal diameter, oc-
lusion device used, sheath size required, hemodynamic data
ncluding Q p/Q s and procedural complications. Angio-
rams were reviewed in 56 of 62 patients to define ductal
orphology and presence of an immediate post-implant
esidual shunt. Follow-up data including duration of
ollow-up and the presence of residual shunting noted by
bbreviations
nd Acronyms
DO  Amplatzer Ductal
ccluder
DA  U.S. Food and Drug
dministration
DA  patient ductus
rteriosuschocardiography were recorded.tatistical analysis. The variables are presented as a mean 
D. No statistical comparisons were made, as the data
ertain to a single treatment group.
esults
total of 62 patients were included in the study. Indica-
ions for cardiac catheterization included primarily the
ntention to close the PDA in 52 (48 with congestive heart
ailure and/or failure to thrive, 3 with left ventricular
ilation, and 1 with a residual PDA following surgical
igation). In 10 patients, catheterization was primarily indi-
ated for evaluation of pulmonary vascular resistance (n 
), and evaluation and potential treatment of other cardio-
ascular anomalies (n  5), but PDA occlusion was none-
heless performed at the same procedure. Of the 62 patients
ncluded in the study, 30 of 62 (48%) had associated defects
Table 1). Fifteen patients had a restrictive ventricular septal
efect (11 in isolation, 4 associated with a small atrial septal
efect) and thus did not require surgical closure. One
atient with truncus arteriosus had a PDA from the right
ubclavian artery occluded post-operatively. There was 1
atient with trisomy 21 and atrioventricular canal with
evere failure to thrive. The PDA was large and closure was
ndicated pre-operatively to reduce volume overload and
llow for somatic growth. In the patient with interrupted
nferior vena cava, a transhepatic approach was used to
eliver the ADO.
The mean age at catheterization was 4.7  2.8 months
range 16 days to 1.2 years). The mean weight at catheter-
zation was 4.6  0.9 kg (range 2.5 to 6 kg). The mean
ngiographic minimal PDA diameter was 2.9  1.1 mm
ith a range of 1 to 7.3 mm. The mean Q p/Q s ratio
available in 60 of 62 patients) calculated by the Fick
ethod was 3.3  1.8 (range 1 to 10.7) to 1. Classification
f ductal morphology as described by Krinchenko et al. (3)
as available in 56 of 62 patients: There were 40 patients
ith type A, 12 with type C, 1 with type D, and 2 with type
ductus morphology. One patient had a PDA arising from
Table 1. Associated Defects of Participants
Associated Defect n
None 32
Atrial septal defect 9
Ventricular septal defect 11
Atrial and ventricular septal defect 4
Interrupted inferior vena cava 1
Aortic hypoplasia with branch pulmonary stenosis 1
Cleft mitral valve 1
Scimitar syndrome 1
Complete atrioventricular canal 1Truncus arteriosus 1
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1297he subclavian artery. Angiograms were not available for
eview in 6 patients and no classification was assigned.
Successful device placement was achieved in 58 of 62
atients (94%), with all 4 unsuccessful cases before the
vailability of the ADO. There was procedural failure in 3
atients. In 2 of the patients, the attempt at closure was
borted due to the inability to stabilize multiple coils within
he PDA using the bioptome technique for delivery, and the
atients were referred for surgical closure. In 1 patient, a
ianturco-Grifka Vascular Occluder Device was used to
cclude the PDA. During deployment, a portion of the filler
ire was extruded from the “sack” upon removal of the
usher wire resulting in a portion of the filler wire protrud-
ng in the pulmonary artery. The patient was referred for
urgical removal of the device and surgical ligation of the
DA. A single patient weighing 5 kg with a PDA minimal
iameter of 4 mm had successful placement of 7 coils, but
ltimately required surgical removal of the coils with PDA
igation 3 days following the procedure due to significant
esidual shunt and hemolysis requiring blood transfusion.
rocedural characteristics including type of device used for
DA occlusion, as well as arterial and venous sheath sizes
re listed in Table 2. The mean fluoroscopic time was 34 
2 min (range 10.5 to 112 min). Complications included
ight femoral vein trauma in addition to new onset tricuspid
nsufficiency in 1 patient (weight: 2.5 kg), transfusion of
acked red blood cells in 3 patients, referral for surgery in
patients (2 due to aborted procedure and 2 due to device
alfunction, described above). There were no arterial
omplications noted at follow-up. No strokes or deaths
ccurred.
Follow-up data were available in 57 of 58 patients who
nderwent successful device implantation. The mean
ollow-up time for the 57 patients was 32  37 months.
mmediate residual shunting was present angiographically
n 29 of 58 (50%) patients who underwent successful device
mplantation. No patient had residual shunting at last
ollow-up by color flow Doppler. Complete echocardio-
raphic data (left pulmonary artery and aortic Doppler
Table 2. Description of Devices Used for Closure
Device n Arterial Sheath Venous Sheath
Coil 25 4- to 5-F 4- to 6-F
Single 15
Multiple 10
ADO 33 4- to 5-F 5- to 7-F
5/4 8
6/4 12
8/6 11
10/8 2
GGVOD 4 4-F 8-F
7 mm 4tADO Amplatzer Ductal Occluder; GGVOD Gianturco-Grifka Vascular Occluder Device.nterrogation) in addition to evaluation for residual shunting
as available for 46 of 57 patients. There was flow acceleration
n the descending aorta in 2 patients on follow-up echocardio-
ram. One patient received a coil (0.038 inches  5 cm  4
m) at a weight of 2.8 kg and was noted to have a peak
elocity in the descending aorta of 2.9 m/s at 1-year post-
rocedure follow-up. The other patient received a 5/4 ADO
evice at 3.6 kg and had a peak velocity in the descending aorta
f 2.3 m/s at 4 months post-procedure follow-up. These 2
atients continue to be followed as outpatients without further
ntervention. There were 4 patients with flow acceleration
oted in the left pulmonary artery. In 1 patient who received
ultiple coils, there was persistent mild left pulmonary artery
tenosis with a peak velocity of 2.6 m/s by Doppler examina-
ion 11.8 years after occlusion. The other 3 patients received
DO devices (5/4 device in 2, 10/8 device in 1) had a peak
elocity of 2.3 to 2.5 m/s by Doppler examination at an average
f 1.9 years follow-up.
iscussion
ranscatheter closure of PDAs is rapidly becoming the
reatment of choice at most centers in larger infants,
hildren, and adults. Since the initial descriptions of PDA
losure with Gianturco coils, there have been various tech-
iques for coil delivery reported to achieve greater coil
tability during closure (4–6). The most frequent compli-
ation using Gianturco coils has been coil embolization in
p to 10% of cases (7). Detachable coils were created to
ddress the lack of control during implantation and release
f the Gianturco coils, with a decrease in reported emboli-
ation rates (7). Despite high success rates for ductal closure
ith coils, these devices were created for occlusion of other
ascular structures and were not made to conform to conical
hape of most PDAs (type A). Several devices have been
eveloped specifically for PDA closure. The Nit-Occlud
PFM Medical, Carlsbad, California) coil occlusion system
s composed of a stainless steel coil that, once released,
ssumes a biconical configuration and can be delivered in a
ontrolled fashion. In addition, it can be repositioned or
etrieved after delivery if necessary (8). The Nit-Occlud is
ot currently approved by the U.S. Food Drug Administra-
ion (FDA). Currently, the only FDA-approved device for
DA closure is the ADO (AGA Medical Corporation,
lymouth, Minnesota). It is a self-expanding conical device
ith a single (aortic) retention skirt and is composed of a
itinol wire mesh with polyester fabric sewn into the mesh
o induce thrombosis; it received FDA approval in May
003. It is available in a wide variety of sizes and is delivered
ransvenously via a 6- to 8-F sheath as per current manu-
acturer recommendations. This device is also fully retriev-
ble via its delivery cable before device release (9). A newer
eneration of the ADO has been developed to contend with
he large variation in ductal size and morphology. The
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1298DO II is a fully retrievable device, also made of a Nitinol
esh, possessing a double disc design (an aortic and a
ulmonary retention skirt) that articulate with a central plug
hat is sized to the diameter of the midpoint of the PDA.
ifferent from the currently approved ADO device, there is
o fabric sewn into the device. It is a lower profile device
uitable for tubular PDAs or complex type D PDAs. It is
urrently undergoing a prospective clinical trial under an
nvestigational device exemption with conditional FDA
pproval for 192 subjects at 25 centers. The weight and age
estrictions for use of the ADO II are identical to those of
he ADO.
Despite current manufacturer recommendations regard-
ng patient age and size, PDAs can be successfully occluded
n small infants with few complications, avoiding a thora-
otomy and its associated morbidities (10,11). In our expe-
ience, 58 of 62 (94%) patients had successful closure of
heir PDA. Retrospective review of the 4 implant failures
evealed favorable ductal morphology for ADO device
cclusion. Accordingly, had these patients undergone PDA
cclusion after the ADO became available, we believe they
ould likely have had successful procedures, at least based
n their suitable ductal morphology. Our experience sug-
ests that the majority of infants weighing 6 kg can
ndergo PDA device occlusion safely and effectively. We do
ot generally advocate transcatheter PDA closure in infants
eighing 6 kg if the PDA is small and the patient is
symptomatic. Instead, we believe such patients should be
onitored and considered for catheter-based closure when
hey are older and larger. However, symptomatic infants6
g with moderate-to-large PDAs pose a therapeutic di-
emma. For most infants in this weight range in the current
ra, percutaneous closure of their PDA will be best achieved
sing the ADO device because of its transvenous delivery,
avorable profile, and easy retrievability. We believe that
espite current FDA labeling to the contrary, we demon-
trated that the ADO device can be used safely “off label” in
nfants 6 kg.
Based on our experience, we have generally offered
atheter-based closure of PDA as the procedure of choice
or symptomatic infants 4 kg. Moreover, in carefully
elected symptomatic patients with echocardiograms sug-
esting a suitable conical PDA morphology, PDA occlusion
sing the ADO in our institution has been performed safely
n infants weighing as little as 2.5 kg. Although it is difficult
o establish an exact lower weight limit for the safe use of
he ADO device (due to the highly variable morphological
haracteristics of the PDA and adjacent aorta), our current
ecommendations are as follows: 1) in some symptomatic
hildren weighing 2.5 to 4 kg, consideration should be given
o attempting PDA closure using the ADO device if the
uctal morphology seems appropriate on echocardiography
i.e., conical in shape and with some area of constriction);
nd 2) in most children weighing 4 to 6 kg, ADO devicelosure should be the primary therapy. Because the ADO
evice can be easily retrieved if PDA closure should prove
nsatisfactory (e.g., due to device protrusion), we believe
hat the risk of attempting PDA closure using the ADO
evice is overall very low, such that surgical PDA ligation
hould be considered as a secondary option for patients 2.5
o 6 kg in whom transcatheter closure either fails or is
eemed unsuitable.
tudy limitations. A limitation of the study was its retro-
pective nature. Additionally, the study spans a broad era,
uring which devices available for percutaneous PDA clo-
ure varied; hence, a consistent PDA occlusion algorithm
as not possible across the study period. Technical advances
uring this time, most significantly the ADO, were not
vailable to patients in the early part of the study. Lastly, our
atabases permitted tracking of infants who were referred
or cardiac catheterization, and in whom placement of a
evice within the PDA was attempted. It was logistically
mpractical to track infants 6 kg who might have had a
DA at catheterization, but in whom percutaneous closure
as never attempted. Although we believe that these pa-
ients would be very few in number, precise numbers are not
vailable, and our study was limited to reporting those
nfants in whom a device placement attempt was made.
onclusions
ith the current armamentarium of devices available for
DA closure, the majority of infants weighing 2.5 to 6 kg
an safely and successfully undergo PDA occlusion in the
atheterization laboratory.
eprint requests and correspondence: Dr. Henri Justino, Mul-
ins Cardiac Catheterization Laboratories, Texas Children’s Hos-
ital, 6621 Fannin, MC 19345-C, Houston, Texas 77030. E-mail:
justino@bcm.edu.
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